News

Vivani Medical's New Financing Fuels Growth of NPM-139

Vivani Medical's New Financing Fuels Growth of NPM-139

Vivani Medical's Funding Enhances Development Plans

Vivani Medical, Inc. is making significant strides in its business operations, further invigorating its growth plans. One notable highlight is the recent announcement of a robust $10M equity financing aimed at accelerating the development of its semaglutide implant, known as NPM-139. This funding positions Vivani to enhance its research and clinical development efforts, particularly following promising weight loss data from an ongoing study.

Strategic Advancements in Drug Implants

The Race to advance NPM-139 has gained added momentum with encouraging weight loss results observed in preclinical studies. These developments are complemented by the successful outcomes of the LIBERATE-1 Phase 1 clinical trial of NPM-115, which also suggests a favorable trajectory for Vivani's future clinical endeavors. The clinical applications of semaglutide-based therapies have shown promising adoption trends, indicating that Vivani is strategically placing itself at the forefront of chronic disease treatment.

Leadership Insights on Recent Progress

Gregg Williams, Chairman of the Board, shared thoughts on the financing announcement, stating that it showcases strong enthusiasm regarding the advancements in Vivani's NanoPortal™ drug implants. He expressed confidence in the management team's capability to steer this cutting-edge technology toward meaningful therapeutic solutions for chronic diseases like obesity and type 2 diabetes.

Tackling Chronic Diseases

Adam Mendelsohn, Ph.D., the CEO of Vivani, emphasized the strategic focus on NPM-139 as a means to enhance the company’s clinical success and commercial prospects. Given the clinical evidence supporting semaglutide's effectiveness, Vivani is well-positioned to capitalize on emerging market opportunities and innovate in the realm of weight management therapies.

Recent Business Developments

Vivani has made noteworthy moves in the market through a share purchase agreement, revealing a plan to issue approximately 7,936,507 shares of common stock at a closing price of $1.26 per share. This initiative will generate gross proceeds of around $10 million, further solidifying the company's financial position as it eyes expansion into the latter half of 2026.

Pipeline Expansion and Product Spin-off

On the horizon, Vivani announced its intention to spin off Cortigent, Inc., a subsidiary focused on developing advanced brain implant devices for functional recovery in patients. This strategic maneuver aims to establish Cortigent as an independent publicly traded company, thereby unlocking additional value within Vivani's portfolio.

Financial Performance Overview

Analyzing the second quarter financial results reveals that as of June 30, 2025, Vivani reported cash and equivalents of $8.1 million, a decrease from $19.7 million at year-end 2024. This drop correlates with a net loss of $13.4 million over the quarter. However, recent equity purchase agreements promise an influx of capital totaling $21.25 million through mid-2026, providing a more secure financial runway.

Looking at Future Milestones

Vivani remains committed to advancing its NPM-139 program with plans for a detailed program update expected to be released soon. Initiation of clinical development for NPM-139 is anticipated in 2026, alongside the completion of the Cortigent spin-off expected to take place in the latter parts of 2025.

About Vivani Medical

Vivani Medical, Inc. leverages its proprietary NanoPortal™ technology to develop biopharmaceutical implants that deliver drugs steadily over extended periods. The company's flagship product, NPM-139, designed for chronic weight management, promises innovative solutions for patients struggling with adherence to traditional medication regimens. This proprietary technology seeks to enhance patient outcomes and minimize challenges associated with conventional drug delivery systems.

Frequently Asked Questions

What is the recent equity financing amount raised by Vivani Medical?

Vivani Medical recently raised $10M through equity financing aimed at advancing the development of NPM-139.

How does Vivani Medical's technology work?

Vivani utilizes its NanoPortal™ technology to create biopharmaceutical implants that offer prolonged drug delivery, improving medication adherence and overall patient experience.

What does the spin-off of Cortigent mean for Vivani?

The spin-off of Cortigent signifies Vivani's strategy to unlock additional value and focus on its core competencies in drug implant technologies.

When does Vivani expect to initiate the NPM-139 clinical program?

Barring any unforeseen circumstances, Vivani anticipates initiating the clinical development for NPM-139 in 2026.

What challenges does Vivani aim to address?

Vivani focuses on enhancing treatment options for chronic diseases such as obesity and type 2 diabetes, tackling the challenges associated with medication adherence and efficacy.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Shanghai Import Expo Draws 4,000 Global Companies Again

Updated Category News Views 132

Shanghai spent last week making a rather pointed commercial argument: China wants to be seen buying, not merely selling. The ninth China International Import Expo, or CIIE, brought together more than 4,000 overseas companies and participants from 162 countries, regions and international organizations. That is a serious gathering by any reasonable measure, even if the...

Continue Reading
Dario's WebMD Deal Opens a Vast, Unproven Channel Path

Updated Category News Views 85

One partnership can look like a gold mine from across the valley; getting the ore out is another matter entirely. DarioHealth has struck a strategic partnership with WebMD Health Services that could put its multi-condition care platform in front of an enormous commercial ecosystem: more than 3,500 employers and 65 million covered lives. That is a meaningful distribution...

Continue Reading
Getac's Linux Certification Matters at the Rugged Edge

Updated Category News Views 73

Field computers rarely get applause, but they can decide whether a critical operation runs cleanly or turns into a very expensive mess. Getac’s November 19 announcement that its UX10, G140, and V120 rugged devices are certified for Red Hat Enterprise Linux is not the sort of headline that sends investors pounding the table. It is, however, the kind of plumbing work that...

Continue Reading
Colossal's Halloween Campaign Wins Top Communicator Honor

Updated Category News Views 28

A horror-themed fan competition putting money toward hospitalized children is not the usual awards-season material, which is precisely why Colossal's latest recognition lands with some weight. The Phoenix-based professional fundraiser received an Award of Excellence, the top honor at the 32nd annual Communicator Awards, for its Face of Halloween campaign in the Innovation...

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 0

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading
Barcelona Housing Summit Puts Affordability on the Map

Updated Category News Views 169

A packed Barcelona hall cannot magically unjam a housing market, but it can force the grown-ups in the room to stare at the mess. Housing World Summit, known as HOWS Barcelona, closed its first edition with 1,530 attendees and a broad cast: city officials, governments, developers, investors, third-sector groups and academics. That mix matters because affordable housing is...

Continue Reading
SciBase Sets Its 2027 AGM Nominating Committee Early

Updated Category News Views 59

Four names on a committee roster rarely make anyone pound the table, and they should not. Still, SciBase Holding has put an important bit of corporate housekeeping in place for its 2027 Annual General Meeting: the nominating committee that will handle shareholder-facing governance work ahead of the May 20 meeting in Stockholm. For a small listed medical-technology...

Continue Reading
Gene Editing’s Steady Revenue Engine Is Taking Shape

Updated Category News Views 87

Gene editing is finally starting to look less like a science-fair moonshot and more like a working supply chain. That distinction matters. The latest market estimate puts the global gene editing market at $5.23 billion in 2026 and projects $8.49 billion by 2031, a 10.1% compound annual growth rate. Respectable growth, certainly, but the real investment story is not a...

Continue Reading
MSD's AI Drug Bet Has Promise, but Plenty to Prove

Updated Category News Views 66

A promising molecule remains a very expensive guess until biology agrees. That is the sober lens for MSD's newly announced research collaboration with Isomorphic Labs: potentially meaningful science, certainly interesting strategic positioning, and absolutely no reason yet to start penciling in product sales. One Oncology Target, Not a Finished Drug On November 19, 2026,...

Continue Reading
AI Search Is Squeezing Clicks, Not Killing Content Yet

Updated Category News Views 121

A search result that answers the question before earning a click is a nasty little disruption, and marketers are plainly feeling around for solid ground. Goodfirms surveyed 192 content marketing professionals for its 2026 Content Engagement Metrics report, and the headline is more resilient than the prevailing panic: 66.3% said organic website traffic grew over the prior...

Continue Reading

Top 5 Most Recently Viewed Articles

EQT AB Faces Challenges Following UBS's Rating Cut

Updated Category News Views 124

EQT AB Stock Drops After UBS Downgrade Recently, shares of EQT AB (ST:EQTAB) took a hit as UBS decided to downgrade the stock from "neutral" to "sell." This change in outlook comes amid rising worries over valuation risks and anticipated earnings in the short term. Market Response and Current Trading Situation Following the downgrade, EQT AB saw its trading price dip by...

Continue Reading
AMTD's 'The Last Dance' Sets Record in Hong Kong Film Scene

Updated Category News Views 221

AMTD's Groundbreaking Film Success AMTD Group Inc., alongside its subsidiaries AMTD IDEA Group (NYSE: AMTD; SGX: HKB) and AMTD Digital Inc. (NYSE: HKD), has achieved a remarkable milestone in the film industry with its new release, 'The Last Dance.' This film has not only shattered nine major records in Hong Kong's cinematic landscape but has also surpassed the impressive...

Continue Reading
Community Healthcare Trust Boosts Q4 Dividend Reflecting Growth

Updated Category News Views 441

Community Healthcare Trust Increases Dividend for Fourth Quarter Community Healthcare Trust Incorporated (NYSE: CHCT) has recently made an exciting announcement regarding its upcoming dividend. This decision reflects the company's ongoing commitment to delivering value to its shareholders and demonstrates its robust financial health. Many investors eagerly await the news...

Continue Reading
NielsenIQ and OpenBrand Partner to Enhance Market Insights

Updated Category News Views 1043

NielsenIQ and OpenBrand Forge a Revolutionary Alliance NielsenIQ (NIQ) stands at the forefront of consumer intelligence, and their recent partnership with OpenBrand is set to redefine the landscape of market intelligence in the consumer electronics sector. This collaboration harnesses both companies' strengths to offer advanced solutions designed for retailers,...

Continue Reading
Florida Quantum Initiative Sparks Revolutionary Tech Development

Updated Category News Views 327

Florida Quantum Initiative Launched to Boost Technology Innovation MIAMI — Just recently, leaders from Florida's technology sector proclaimed the launch of Florida Quantum, a groundbreaking initiative designed to accelerate and organize the state's quantum economy. This exciting announcement came during the eMerge Americas' Tech Basel AI Summit Miami, showcasing...

Continue Reading